1. Home
  2. FRO vs INDV Comparison

FRO vs INDV Comparison

Compare FRO & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frontline Plc

FRO

Frontline Plc

HOLD

Current Price

$37.99

Market Cap

4.8B

ML Signal

HOLD

Logo Indivior PLC

INDV

Indivior PLC

HOLD

Current Price

$40.43

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRO
INDV
Founded
1985
N/A
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.4B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
FRO
INDV
Price
$37.99
$40.43
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$37.67
N/A
AVG Volume (30 Days)
3.5M
1.6M
Earning Date
05-22-2026
06-08-2026
Dividend Yield
4.85%
N/A
EPS Growth
N/A
8100.00
EPS
N/A
0.69
Revenue
N/A
$1,239,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$34.05
$59.86
Revenue Growth
N/A
4.29
52 Week Low
$18.04
$15.00
52 Week High
$43.10
$42.81

Technical Indicators

Market Signals
Indicator
FRO
INDV
Relative Strength Index (RSI) 52.05 57.41
Support Level $33.79 $35.36
Resistance Level $39.73 $41.00
Average True Range (ATR) 1.77 1.56
MACD -0.09 -0.06
Stochastic Oscillator 41.69 55.32

Price Performance

Historical Comparison
FRO
INDV

About FRO Frontline Plc

Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.

About INDV Indivior PLC

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Share on Social Networks: